focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,096.00
Bid: 12,088.00
Ask: 12,092.00
Change: -14.00 (-0.12%)
Spread: 4.00 (0.033%)
Open: 12,090.00
High: 12,118.00
Low: 12,038.00
Prev. Close: 12,110.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 1-Euro zone economies' plucky Q4 belies troubled growth outlook

Fri, 29th Jan 2021 11:37

* Germany and Spain eke out narrow Q4 growth

* France contracts by less than expected

* But vaccine roll-out issues, restrictions blight outlook

* IMF sees euro zone recovery lagging U.S., Japan

By Paul Carrel and Leigh Thomas

BERLIN/PARIS, Jan 29 (Reuters) - Growth in Germany and Spain
and a smaller-than-expected contraction in France pointed to
resilience in the euro zone economy in the final three months of
last year, but the bright spot belies a more troubled outlook
for the bloc.

In Germany, robust exports helped Europe's largest economy
eke out 0.1% growth in the fourth quarter, staving off
contraction despite a second wave of the new coronavirus
slamming the brakes on consumption, data showed on Friday.

France, the euro zone's second-largest economy, shrank 1.3%
in the final three months of 2020 after the country entered a
second coronavirus lockdown in October to contain a second wave
of infections.

Spain achieved timid quarterly growth of 0.4%. But that has
not stopped Spain from recording its worst-ever annual economic
contraction, with output falling 11% from 2019's level, official
data showed.

"Numbers for Germany, France and Spain showed that GDP was
relatively resilient in Q4," Nicola Nobile at Oxford Economics
wrote in a research note. But he added, "there are not many
indications that this dynamic could have continued in Q1."

"All in all, the disappointing vaccine roll-out so far, the
extension of restrictions in many European countries and the
latest data now point to continued weakness in the eurozone over
the coming months."

The French slump, which followed an 18.5% rebound in the
third quarter after a first lockdown, beat expectations for a 4%
contraction on average in a Reuters poll of 28 economists,
surpassing even the highest estimate of -1.4%.

But France is on tenterhooks to find out in the coming days
whether the government will put the country under a new lockdown
and in particular whether schools will be closed.

In Germany, Chancellor Angela Merkel and state leaders
agreed last week to extend a lockdown until mid-February as the
country, once a role model for fighting the pandemic, struggles
with a second wave and record daily numbers of COVID-19 deaths.

On Wednesday, German government slashed its growth forecast
to 3% this year, a sharp revision from last autumn's estimate of
4.4%, caused by a second coronavirus lockdown.

TRAILING U.S.

The economic outlook across the 19-country euro zone is
being muddied by a row between the European Union and
Anglo-Swedish firm AstraZeneca over its supply of
vaccines to the bloc, and by the return of inflation in Germany.

The International Monetary Fund said this week the euro area
is likely to slip behind the United States in its recovery.

"Recovery paths vary within the group, with the U.S. and
Japan projected to regain end-2019 activity levels in the second
half of 2021, while in the euro area and the United Kingdom
activity is expected to remain below end-2019 levels into 2022,"
the IMF said in its in its World Economic Outlook.

The AstraZeneca supply issue is a blow to Europe's COVID-19
vaccination drive, and the German inflation spike - consumer
prices turned positive and rose in January to 1.6% on the year -
adds to a complex mix of data for the European Central Bank to
assess.

ECB data released on Friday showed lending to euro zone
companies picked up last month though the bloc was probably back
in recession and banks said they were tightening access to
credit amid fear of defaults amid a fresh wave of lockdowns.

The ECB is unlikely to cut its already-record-low policy
because that would do little to revive the pandemic-hit euro
zone economy, five sources told Reuters, playing down concern
about a strong euro.

Traders were left scratching their head this week when Dutch
central bank governor Klaas Knot said the ECB "had room" to push
its Deposit Facility Rate, currently at minus 0.5%, further
below zero if needed to stem a rally in the euro EUR=.

The sources said Knot had raised the rate cut issue at the
ECB's policy meeting last week but the discussion was "marginal"
and not considered part of the ECB's policy strategy, which is
now focussed on bond purchases and cheap loans to banks.

"ECB communication could be such a powerful tool but is
really very confusing," BofA analysts said in a research note.

(Additional reporting by Belén Carreño and Joao Manuel Vicente
Mauricio in Madrid and by Francesco Canepa, Balazs Koranyi and
Frank Siebelt in Frankfurt; editing by Larry King)

More News
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more
20 May 2024 07:22

AstraZeneca announces $1.5bn Singapore manufacturing facility

(Sharecast News) - AstraZeneca announced plans to construct a $1.5bn manufacturing facility in Singapore on Monday, dedicated to the production of antibody drug conjugates (ADCs).

Read more
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.